India, Sept. 9 -- Shilpa CDMO (customer-facing brand of Shilpa Pharma Lifesciences), a dedicated complex small-molecule contract development and manufacturing organisation will launch next month at CPHI Milan 2026 (6-8 October, Fiera Milano).

The new brand, separate from parent company Shilpa Medicare, provides a specialist development and commercial manufacturing partner for biotech and pharma customers with complex small molecules, building on Shilpa's more than 30 years of oncology expertise.

Keshav Bhutada, Chief Executive Officer of Shilpa CDMO, said, "We have long been known among our existing partners as incredibly capable, particularly for challenging molecules such as HPAPIs and peptides, and more recently ADC payloads and link...